Abstract：
The quality and quantity of hematopoietic stem cells in apheresis products are essential to the success of peripheral blood hematopoietic stem cell transplantation (PB-HSCT). While the flow cytometry measurement of CD34+ cells as a golden standard for stem cell count is labor and cost-intensive, hematopoietic progenitor cell number evaluated by XN Sysmex series automated hematology analyzers (XN-HPC) is suggested as a surrogate marker.
We evaluated the correlation and consistency of XN-HPC and CD34+ cell count in apheresis samples from both allogeneic donors and autologous patients during PB-HSCT.
Good correlation and consistency were observed between XN-HPC and CD34+ cell counts in harvests collected from healthy donors (R = .852) rather than autologous patients (R = .375). Subgroup analysis showed that the correlation was especially poor when autologous patients used plerixafor as an additional mobilizer or were diagnosed with multiple myeloma (MM). In the setting of allogeneic transplantation, the correlation coefficients were even better in samples from non-first-round apheresis (R = .951), with high white blood cell (WBC) counts (R = .941), or having successful engraftment within 2 weeks (R = .895). ROC analysis suggested that an optimal XN-HPC count of 1127 × 106 /L best predicted a sufficient yield of CD34+ stem cells, with diagnostic sensitivity and specificity being 92% and 72%, respectively (AUC = 0.852).
XN-HPC is a sufficient quantitative marker for stem cell assessment of harvest yield in allogeneic but not autologous HSCT.
We evaluated the correlation and consistency of XN-HPC and CD34+ cell count in apheresis samples from both allogeneic donors and autologous patients during PB-HSCT.
Good correlation and consistency were observed between XN-HPC and CD34+ cell counts in harvests collected from healthy donors (R = .852) rather than autologous patients (R = .375). Subgroup analysis showed that the correlation was especially poor when autologous patients used plerixafor as an additional mobilizer or were diagnosed with multiple myeloma (MM). In the setting of allogeneic transplantation, the correlation coefficients were even better in samples from non-first-round apheresis (R = .951), with high white blood cell (WBC) counts (R = .941), or having successful engraftment within 2 weeks (R = .895). ROC analysis suggested that an optimal XN-HPC count of 1127 × 106 /L best predicted a sufficient yield of CD34+ stem cells, with diagnostic sensitivity and specificity being 92% and 72%, respectively (AUC = 0.852).
XN-HPC is a sufficient quantitative marker for stem cell assessment of harvest yield in allogeneic but not autologous HSCT.
摘要：
背景：单采产品中造血干细胞的质量和数量对外周血造血干细胞移植（PB-HSCT）的成功至关重要。虽然流式细胞术测量CD34+细胞作为干细胞计数的黄金标准是劳动力和成本密集型的，建议将XNSysmex系列自动血液学分析仪(XN-HPC)评估的造血祖细胞数量作为替代标记.
方法：我们评估了PB-HSCT期间来自同种异体供体和自体患者的单采术样品中XN-HPC和CD34+细胞计数的相关性和一致性。
结果:在从健康供体(R=.852)而不是自体患者(R=.375)收集的收获物中,在XN-HPC和CD34+细胞计数之间观察到良好的相关性和一致性。亚组分析表明，当自体患者使用plerixafor作为额外的动员剂或被诊断为多发性骨髓瘤（MM）时，相关性尤其差。在同种异体移植的背景下，在来自非第一轮单采的样本中，相关系数甚至更好(R=.951)，具有高白细胞（WBC）计数（R=.941），或在2周内成功植入（R=.895）。ROC分析表明，1127×106/L的最佳XN-HPC计数最好地预测CD34干细胞的足够产量，诊断灵敏度和特异性分别为92%和72%，分别（AUC=0.852）。
结论：XN-HPC是用于评估同种异体但非自体HSCT中的干细胞收获率的足够的定量标志物。
方法：我们评估了PB-HSCT期间来自同种异体供体和自体患者的单采术样品中XN-HPC和CD34+细胞计数的相关性和一致性。
结果:在从健康供体(R=.852)而不是自体患者(R=.375)收集的收获物中,在XN-HPC和CD34+细胞计数之间观察到良好的相关性和一致性。亚组分析表明，当自体患者使用plerixafor作为额外的动员剂或被诊断为多发性骨髓瘤（MM）时，相关性尤其差。在同种异体移植的背景下，在来自非第一轮单采的样本中，相关系数甚至更好(R=.951)，具有高白细胞（WBC）计数（R=.941），或在2周内成功植入（R=.895）。ROC分析表明，1127×106/L的最佳XN-HPC计数最好地预测CD34干细胞的足够产量，诊断灵敏度和特异性分别为92%和72%，分别（AUC=0.852）。
结论：XN-HPC是用于评估同种异体但非自体HSCT中的干细胞收获率的足够的定量标志物。
